Starpharma Expands research program with Genentech
- Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP
- The initial agreement was signed in December 2021 and involves Star pharma designing and synthesising dendrimer-based drug conjugates for Genentech to test and characterise
- The expanded program includes additional drug conjugates with no changes to the original agreement terms
- Throughout the partnership, the platform will receive research fees which are not expected to be material and there are also no material costs to Star pharma
- SPL shares are down 5.56 per cent and trading at 68 cents at 12:28 pm AEST
